Gastric Cancer
Advertisement
A recent systematic review evaluated the relationship between NLR and the prognosis of patients who receive NAC.
The phase III study found that regorafenib improved overall survival in patients with refractory advanced gastric cancer.
The SOX chemotherapy regimen for gastric cancer consists of S-1, an oral fluoropyrimidine, in combination with oxaliplatin.
Tislelizumab shows significant survival benefits in first-line treatment for gastric and esophageal cancers.
FDA approval of the first and only CLDN18.2-targeted treatment follows two successful phase III clinical trials.
Dr. Leong showcases the highly anticipated results of the TOPGEAR study in patients with resectable G/GEJ adenocarcinoma.
The addition of preop CRT to periop chemo may not have added OS benefit for patients with resectable G/GEJ adenocarcinoma.
Dr. Wainberg reviews the data on GI malignancies and notes that it is unclear who should receive radiation before surgery.
Dr. Janjigian shares an overview of the DESTINY-Gastric03 study and the history of T-Dxd for gastric and GEJ cancers.
Trastuzumab deruxtecan, pembrolizumab, and chemotherapy shows benefits in advanced or metastatic esophageal, gastric, or GEJA
These data may support the approval of pembro plus trastuzumab and chemo in patients with HER2+ metastatic G/GEJ cancer.
Researchers utilized a deep learning model to combine data and develop personalized treatment response predictions.
Dr. Sanford shares unique experiences and insights on her life and career in this interview with GI Oncology Now.
Currently, there is little research on the comparative accuracy of mpMRI versus DECT.
Grace-Ann Fasaye discusses the elevated lifetime risk of gastric cancer in patients with CDH1 gene variants.
Researchers reported that a buildup of lactate was most notable in chemotherapy-resistant cancer tissues.
Drs. Uboha and Karasic discuss the benefits and considerations of treating gastric cancer with an anti-CCR8 antibody.
The study’s primary endpoint was the connection between OS and post-recurrence survival.
Drs. David H. Ilson and Nataliya Uboha highlight the final OS results of the phase 3 SPOTLIGHT study.
Claudin 18 isoform 2 is an emerging therapeutic target in gastric and gastroesophageal cancers.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.